Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Human Microbiome Market To Surpass US$ 201.5 Billion By 2026 - Coherent Market InsightsHuman Microbiome Market Report Analyses competitive environment such as key players, future trends, growths, challenges and acquisitions in the market.
High number of collaboration activities between key players and academia Increasing number of collaboration activities between various players in the market and between different players and research institutes is expected to aid in the expansion and development of novel medicines for variety of diseases. * The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology. Request a sample copy of this report: https://www.coherentmarketinsights.com/ Browse 36 Market Data Tables and 35 Figures spread through 220 Pages and in-depth TOC on 'Human Microbiome Market'- Global Forecast to 2026, by Product Type (Foods, Diagnostic Devices/Kits, Drugs, and Others), by Application (Therapeutics, and Diagnostics) Growing incidence of disease conditions in which human microbiome product is used. According to data given by Centre for Disease Control and Prevention in October 2017, Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections in the China and Hong Kong, affecting around 36.1 cases/100,000 person in 2014. Browse Research Report: https://www.coherentmarketinsights.com/ Key Takeaways of the Human Microbiome Market: The global human microbiome market is expected to exhibit a CAGR of 17.5% over the forecast period, owing to increasing prevalence of cardiopulmonary conditions, cancer, and renal diseases. Among application, diagnostics segment held a dominant position in the human microbiome market in 2017, as emergence of diagnosis in early stage of cancer and other diseases is proven to be beneficial in disease management. Key players operating in the global human microbiome market include Enterome Bioscience, Yakult Honsha Co., Ltd., DuPont, Metabiomics Corporation, ViThera Pharmaceuticals, Second Genome Inc., AOBiome LLC, Seres Therapeutics, uBiome, Inc., Rebiotix, Inc., Synthetic Biologics, Inc., MicroBiome Therapeutics LLC, Vedanta BioSciences, Osel, Inc., and Merck & Co., Inc. Buy-Now this research report: https://www.coherentmarketinsights.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|